The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2022 | Safety considerations in CAR-T therapy: patient selection and side effects
Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, shares guidelines on patient selection and patient follow-up after treatment with chimeric antigen receptor T-cell (CAR-T) therapy. Prof. Einsele explains that patients with comorbidities including cardiovascular and pulmonary diseases, as well as renal, liver or hematopoietic dysfunction should not receive CAR-T therapy. It is also important to avoid exposing patients to lymphodepleting treatments prior to leukapheresis. In addition, clinicians should be aware of side effects that can occur long after treatment with CAR-Ts. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
